#Atré

Update on growth strategy mindful of capital cost and stock price. Includes optimization of internal capital, targets for ROE/ROIC, expansion of shareholder benefits, and policy on capital policy and growth investments through FY2026.

Obtained manufacturing and marketing authorization for insomnia treatment drug Daridorexant (QUVIVIQ®) in Taiwan; partner Holling Bio-Pharma Corp. scheduled to launch within 2026. Milestone payments and royalty revenues are expected.

For the fiscal year ending February 2026, net sales reached 3,632 million yen (YoY +5.6%), operating income was 378 million yen (+25.2%), and net income attributable to owners of parent was 284 million yen (+30.9%), all exceeding forecasts.

For the fiscal year ending February 2026, net sales were JPY 3,632 million (16.9% YoY increase), operating income was JPY 378 million (73.6% YoY increase), and net income attributable to owners of the parent was JPY 284 million (3.6% YoY increase).

Nexera Pharma announced the submission of a manufacturing and marketing authorization application for the dual orexin receptor antagonist daridorexant in South Korea, aiming for approval in 2027.

For the third quarter of the fiscal year ending February 2026, net sales were 2,693,316 thousand yen (17.6% increase YoY), operating income was 305,549 thousand yen (80.5% increase YoY), and net income attributable to owners of parent for the quarter was 256,740 thousand yen (73.2% increase YoY).